Hatcher RA, Trussell TJ, Stewart FH, et
al., eds. Contraceptive technology. 17th ed. New York: Ardent
Media, 1998.
Drew WL, Blair M, Miner RC, Conant M. Evaluation
of the virus permeability of a new condom for women. Sex Transm Dis
1990;17:110--2.
Richardson BA. Nonoxynol-9 as a vaginal
mircrobicide for prevention of sexually transmitted infections. JAMA
2002;287:1171--2.
Cates W, Stone KM. Family planning, sexually
transmitted diseases, and contraceptive choice: a literature update---part
I. Fam Plann Perspectives 1992;24:74--84.
Kamb ML, Fishbein M, Douglas JM, et al.
HIV prevention counseling reduces high risk behaviors and sexually
transmitted diseases: results from a multicenter, randomized controlled
trial (Project RESPECT). JAMA 1998;280:1161--7.
U.S. Preventive Services Task Force. Guide
to clinical preventive services. 2nd ed. Baltimore, MD:
Williams & Wilkins, 1996.
American Academy of Pediatrics and American
College of Obstetricians and Gynecologists. Guidelines for perinatal
care. 4th ed. Washington, DC: American Academy of Pediatrics
and American College of Obstetricians and Gynecologists, 1997.
American College of Obstetricians and
Gynecologists. Antimicrobial therapy for obstetric patients. Washington,
DC: American College of Obstetricians and Gynecologists, March 1998.
(Educational bulletin, no. 245.)
American College of Obstetricians and
Gynecologists. Committee opinion: primary and preventive care. Washington,
DC: American College of Obstetricians and Gynecologists, December 1999.
(Periodic assessments, no. 229.)
Zanetti AR, Tanzi E, Newell ML. Mother-to-infant
transmission of hepatitis C virus. J Hepatol 1999;31(Suppl):96--100.
Burns DN, Minkoff H. Hepatitis C: screening
in pregnancy. Obstet Gynecol 1999;94:1044.
American College of Obstetricians and
Gynecologists. Viral hepatitis in pregnancy. Washington, DC: American
College of Obstetricians and Gynecologists, July 1998. (Educational
bulletin, no. 248.)
American Academy of Pediatrics and American
College of Obstetricians and Gynecologists. Human immunodeficiency
virus screening: joint statement of the AAP and ACOG. Pediatrics 1999;104:128.
Institute of Medicine. Reducing the odds:
preventing perinatal transmission of HIV in the United States. Washington,
DC: National Academy Press, 1999.
CDC. USPHS/IDSA Prevention of Opportunistic
Infections Working Group. 2001 USPHS/IDSA guidelines for the prevention
of opportunistic infections in persons infected with human immunodeficiency
virus. Atlanta, GA: US Department of Health and Human Services, Centers
for Disease Control and Prevention, November 28, 2001. Available at http://www.aidsinfo.nih.gov/guidelines/.
CDC. Testing for antibodies to human immunodeficiency
virus type 2 in the United States. MMWR (in press).
Department of Health and Human Services,
Henry J. Kaiser Foundation Panel on Clinical Practices for the Treatment
of HIV Infection. Guidelines for the use of antiretroviral agents in
HIV-infected adults and adolescents. US Department of Health and Human
Services, February 4, 2002. Available at http://www.aidsinfo.nih.gov/guidelines/.
Carpenter CJ, Cooper DA, Fischl MA, et
al. Antiretroviral therapy in adults: updated recommendations of the
International AIDS Society---USA Panel. JAMA 2000;283:381--90.
CDC. CDC National Prevention Plan. Federal
Register 2002 (in press).
CDC. HIV Prevention case management: guidance.
Atlanta, GA: US Department of Health and Human Services, Public Health
Service, September 1997.
Fowler MG, Simonds RJ, Roongpisuthipong
A. Update on perinatal HIV transmission. Pediatr Clin North Am 2000;47:241--60.
CDC. Recommendations for the use of antiretroviral
drugs in pregnant HIV-1 infected women for maternal health and interventions
to reduce perinatal HIV-1 transmission in the United States. Atlanta,
GA: US Department of Health and Human Services, February 4, 2002. Available
at http://www.aidsinfo.nih.gov/guidelines/.
CDC. Guidelines for the use of antiretroviral
agents in pediatric HIV infection. Atlanta, GA: US Department of Health
and Human Services, August 8, 2001. Available at http://www.aidsinfo.nih.gov/guidelines/.
Wald A. New therapies and prevention strategies
for genital herpes. Clin Infect Dis 1999;28(Suppl):S4--S13.
Bodsworth NJ, Crooks RJ, Borelli S, et
al. Valaciclovir versus acyclovir in patient-initiated treatment of
genital herpes: a randomized, double-blind clinical trial. Genitourin
Med 1997;73:110--6.
Patel R, Bodsworth NJ, Wooley P, et al.
Valaciclovir for the suppression of recurrent genital HSV infection:
a placebo controlled study of once-daily therapy. Genitourin Med 1997;73:105--9.
Spruance S, Trying S, Degregorio B, Miller
C, Beutner K, the Valaciclovir HSV Study Group. A large-scale, placebo-controlled,
dose-ranging trial of peroral valacyclovir for episodic treatment of
recurrent herpes genitalis. Arch Int Med 1996;156:1729--35.
Fife KH, Barbarash RA, Rudolph T, Degregorio
B, Roth RE. Valaciclovir versus acyclovir in the treatment of first-episode
genital herpes infection: results of an international, multicenter,
double-blind randomized clinical trial. Sex Transm Dis 1997;24:481--6.
Reitano M, Tyring S, Lang W, et al. Valaciclovir
for the suppression of recurrent genital herpes simplex virus infection:
a large-scale dose range-finding study. J Infect Dis 1998;178:603--10.
Chosidow O, Drouault Y, Lecontae-Veyriac
F, et al. Famciclovir vs. aciclovir in immunocompetent patients with
recurrent genital herpes infections: a parallel-groups, randomized,
double-blind clinical trial. Br J Dermatol 2001:144:818--24.
Diaz-Mitoma F, Sibbald RG, Shafran SD,
Boon R, Saltzman RL. Oral famciclovir for the suppression of recurrent
genital herpes: a randomized controlled trial. JAMA 1998;280:887--92.
Loveless M, Harris W, Sacks S. Treatment
of first episode genital herpes with famciclovir. In: Programs and
abstracts of the 35th Interscience Conference on Antimicrobial Agents
and Chemotherapy, San Francisco, California, 1995.
Mertz GJ, Loveless MO, Levin MJ, et al.
Oral famciclovir for suppression of recurrent genital herpes simplex
virus infection in women: a multicenter, double-blind, placebo-controlled
trial. Arch Intern Med 1997;157:343--9.
Sacks SL, Aoki FY, Diaz-Mitoma F, Sellors
J, Shafran SD. Patient-initiated, twice-daily oral famciclovir for
early recurrent genital herpes: a randomized, double-blind multicenter
trial. JAMA 1996;276:44--9.
Henry RE, Wegmann JA, Hartle JE, Christopher
GW. Successful oral acyclovir desensitization. Ann Allergy 1993;70:386--8.
Reiff-Eldridge RA, Heffner CR, Ephross
SA, Tennis PS, White AD, Andrews EB. Monitoring pregnancy outcomes
after prenatal drug exposure through prospective pregnancy registries:
a pharmaceutical company commitment. Am J Obstet Gynecol 2000;182:159--63.
Scott LL, Sanchez PJ, Jackson GL, Zeray
F, Wendel GD, Jr. Acyclovir suppression to prevent cesarean delivery
after first-episode genital herpes. Obstet Gynecol 1996;87:69--73.
Brocklehurst P, Kinghorn G, Carney O,
et al. A randomised placebo controlled trial of suppressive acylovir
in late pregnancy in women with recurrent genital herpes infection.
Br J Obstet Gynaecol 1998;105:275--80.
Thorpe EM, Stamm WE, Hook EW, et al. Chlamydial
cervicitis and urethritis: single dose treatment compared with doxycycline
for seven days in community-based practices. Genitourin Med 1996;72:93--7.
Stamm WE, Hicks CB, Martin DH, et al.
Azithromycin for empirical treatment of the nongonococcal urethritis
syndrome in men: a randomized double-blind study. JAMA 1995;274:545--9.
Adair CD, Gunter M, Stovall TG, McElvoy
G, Veille JC, Erment JM. Chlamydia in pregnancy: a randomized trial
of azithromycin and erithromycin. Obstet Gynecol 1998;91:165--8.
Wehbeh HA, Ruggeirio RM, Shakem S, Lopez
G, Ali Y. Single dose azithromycin for chlamydia in pregnant women.
J Reprod Med 1998;43:509--14.
Moran JS, Levine WC. Drugs of choice for
the treatment of uncomplicated gonococcal infections. Clin Infect Dis
1995;20(Suppl 1);S47--S65.
Haimovici R, Roussel TJ. Treatment of
gonococcal conjunctivitis with single-dose intramuscular ceftriaxone.
Am J Ophthalmol 1989;107:511--4.
Hauth JC, Goldenberg RL, Andrews WW, DuBard
MB, Copper RL. Reduced incidence of preterm delivery with metronidazole
and erythromycin in women with bacterial vaginosis. N Engl J Med 1995;333:1732--6.
Morales WJ, Schorr S, Albritton J. Effect
of metronidazole in patients with preterm birth in preceding pregnancy
and bacterial vaginosis: a placebo-controlled, double-blind study.
Am J Obstet Gynecol 1994;171:345--9.
McDonald HM, O'Loughlin JA, Vigneswaran
R, et al. Impact of metronidazole therapy on preterm birth in women
with bacterial vaginosis flora (Gardnerella vaginalis): a randomised,
placebo controlled trial. Br J Obstet Gynaecol 1997;104:1391--7.
Jackson P, Ridley WJ, Pattison NS. Single
dose metronidazole prophylaxis in gynaecological surgery. NZ Med J
1979;89:243--5.
Willis AT. Metronidazole in the prevention
and treatment of Bacteroides infections in gynaecological patients.
Lancet 1974;2:1540--3.
Persson E, Bergstrom M, Larsson PG, et
al. Infections after hysterectomy: a prospective nationwide Swedish
Study. Acta Obstetrica et Gynecologiaca Scandinavica 1996;75:757--61.
Larsson PG, Platz-Christensen JJ, Forsum
U, Pahlson C. Clue cells in predicting infections after abdominal hysterectomy.
Obstet Gynecol 1991;77:450--2.
Newton ER, Prihoda TJ, Gibbs RS. A clinical
and microbiologic analysis of risk factors for puerperal endometritis.
Obstet Gynecol 1990;75:402--6.
Soper DE, Bump RC, Hurt WG. Bacterial
vaginosis and trichomoniasis vaginitis are risk factors for cuff cellulitis
after abdominal hysterectomy. Am J Obstet Gynecol 1990;163:1016--21.
Watts DH, Krohn MA, Hillier SL, Eschenbach
DA. Bacterial vaginosis as a risk factor for post-cesarean endometritis.
Obstet Gynecol 1990;75:52--8.
Silver HM, Sperling RS, St. Clair PJ,
Gibbs RS. Evidence relating bacterial vaginosis to intraamniotic infection.
Am J Obstet Gynecol 1989;161:808--12.
Bjornerem A, Aghajani E, Maltau JM, Moi
H. Occurrence of bacterial vaginosis among abortion seekers. Tidsskrift
for Den Norske Laegeforening 1997;117:1282--4.
Hamark B, Forssman L. Postabortal endometritis
in chlamydia-negative women---association with preoperative clinical
signs of infection. Gynecol Obstet Invest 1991;31:102--5.
Larsson PG, Bergman B, Forsum U, Platz-Christensen
JJ, Pahlson C. Mobiluncus and clue cells as predictors of PID after
first-trimester abortion. Acta Obstetrica et Gynecologica Scandinavica
1989;68:217--20.
Hillier SL, Martius J, Krohn M, Kiviat
N, Holmes KK, Eschenbach DA. A case-control study of chorioamnionic
infection and histologic chorioamnionitis in prematurity. New Engl
J Med 1998;319:972--8.
Livengood CH, III, Soper DE, Sheehan KL,
et al. Comparison of once-daily and twice-daily dosing of 0.75% metronidazole
gel in the treatment of bacterial vaginosis. Sex Transm Dis 1999;26:137--42.
Sobel J, Peipert JF, McGregor JA, et al.
Efficacy of clindamycin vaginal ovule vs. clindamycin vaginal cream
in bacterial vaginosis. Infect Dis Obstet Gynecol 2002 (in press).
Moi H, Erkkola R, Jerve F, et al. Should
male consorts of women with bacterial vaginosis be treated? Genitourin
Med 1989;65:263--8.
Colli E, Landoni M, Parazzini F, et al.
Treatment of male partners and recurrence of bacterial vaginosis: a
randomised trial. Genitourin Med 1997;73:267--70.
Vejtorp M, Bollerup AC, Vejtorp L, et
al. Bacterial vaginosis: a double-blind randomized trial of the effect
of treatment of the sexual partner. Br J Obstet Gynaecol 1988;95:920--6.
McGregor JA, French JI, Jones W, et al.
Bacterial vaginosis is associated with prematurity and vaginal fluid
mucinase and sialidase: results of a controlled trial of topical clindamycin
cream. Am J Obstet Gynecol 1994;170:1048--59.
Joesoef MR, Hillier SL, Wiknjosastro G,
et al. Intravaginal clindamycin treatment for bacterial vaginosis:
effects on preterm delivery and low birth weight. Am J Obstet Gynecol
1995;173:1527--31.
Vermeulen GM, Bruinse HW. Prophylactic
administration of clindamycin 2% vaginal cream to reduce the incidence
of spontaneous preterm birth in women with an increased recurrence
risk: a randomised placebo-controlled double-blind trial. Br J Obstet
Gynaecol 1999;106:652--7.
Caro-Paton T, Carvajal A, Martin de Diego
I, Martin-Arias LH, Alvarez Requejo A. Is metronidazole teratogenic?
A meta-analysis. Br J Clin Pharmacol 1997;44:179--82.
Burtin P, Taddio A, Ariburnu O, Einarson
TR, Koren G. Safety of metronidazole in pregnancy: a meta-analysis.
Am J Obstet Gynecol 1995;172:525--9.
Piper JM, Mitchel EF, Ray WA. Prenatal
use of metronidazole and birth defects: no association. Obstet Gynecol
1993;82:348--52.
Carey JC, Klebanoff MA, Hauth JC, et al.
Metronidazole to prevent preterm delivery in pregnant women with asymptomatic
bacterial vaginosis. New Engl J Med 2000;342:534--40.
Hay PE, Ugwumadu AHN, Jeffrey I, Manvonda
JT. Oral clindamycin prevents spontaneous preterm birth and mid trimester
miscarriage in pregnant women with bacterial vaginosis. Int J STD AIDS
2001;12(Suppl 2):70--1.
Pearlman MD, Yashar C, Ernst S, Solomon
W. An incremental dosing protocol for women with severe vaginal trichomoniasis
and adverse reactions to metronidazole. Am J Obstet Gynecol 1996;174:934--6.
Klebanoff MA, Carey JC, Hauth JC, et al.
Failure of metronidazole to prevent preterm delivery among pregnant
women with asymptomatic Trichomonas vaginalis infection. New
Engl J Med 2001;345:487--93.
Matsuda S. Clinical study of levofloxacin
(LVFX) on the infectious diseases in the field of obstetrics and gynecology.
Chemotherapy 1992;40:311--23.
Martens MG, Gordon S, Yarborough DR, Faro
S, Binder D, Berkeley A. Multicenter randomized trial of ofloxacin
versus cefoxitin and doxycycline in outpatient treatment of pelvic
inflammatory disease. South Med J 1993;86:604--10.
Peipert JF, Sweet RL, Kahn J, Reilly-Gauvin
K. Evaluation of ofloxacin in the treatment of laparoscopically documented
acute pelvic inflammatory disease (salpingitis). Infect Dis Obstet
Gynecol 1999;7:138--44.
Walker CK, Workowski KA, Washington AE,
Soper D, Sweet RL. Anaerobes in pelvic inflammatory disease: implications
for the Centers for Disease Control and Prevention's guidelines for
treatment of sexually transmitted diseases. Clin Infect Dis 1999;28(Suppl
1):S29--S36.
Witte EH, Peters AA, Smit IB, van der
Linden MC, Mouton RP, van der Meer JW, van Erp EJ. A comparison of
pefloxacin/metronidazole and doxycycline/metronidazole in the treatment
of laparoscopically confirmed acute pelvic inflammatory disease. Eur
J Obstet Gynecol Reprod Biol 1993;50:153--8.
Ridgway GL, Bevan C, Siddle N. Azithromycin
with or without metronidazole compared with cefoxitin, doxycycline
and metronidazole in the treatment of laparoscopy confirmed acute pelvic
inflammatory disease [Abstract]. In: Proceedings of the 11th International
Meeting of the International Society for STD Research, New Orleans.
Fort Lee, New Jersey: International Society for STD Research, 1995.
Cohen CR, Sinei S, Reilly M, et al. Effect
of human immunodeficiency virus type 1 infection upon acute salpingitis:
a laparoscopic study. J Infect Dis 1998;178:1352--8.
Bukesi EA, Cohen CR, Stevens CE, et al.
Effects of human immunodeficiency virus 1 infection on microbial origins
of pelvic inflammatory disease and on efficacy of ambulatory oral therapy.
Am J Obstet Gynecol 1999;18:1374--81.
Irwin KL, Moorman AC, O'Sullivan MJ, et
al. Influence of human immunodeficiency virus infection on pelvic inflammatory
disease. Obstet Gynecol 2000;95:525--34.
Kamb ML. Cervical cancer screening of
women attending sexually transmitted diseases clinics. Clin Infect
Dis 1995;20(Suppl 1): S98--S103.
American Cancer Society. Guidelines for
the cancer related checkup. Atlanta, Georgia: American Cancer Society,
1998.
American College of Obstetricians and
Gynecologists. Routine cancer screening: committee opinion 185. Washington,
DC: American College of Obstetricians and Gynecologists, 1997.
National Cancer Institute Workshop. The
1988 Bethesda System for reporting cervical/vaginal cytological diagnoses.
JAMA 1989;262:931--4.
Jay N, Moscicki AB. Human papillomavirus
infections in women with HIV disease: prevalence, risk, and management
[Review]. AIDS Reader 2000;10:659--68.
Kurman RJ, Henson DE, Herbst AL, Noller
KL, Schiffman MH, National Cancer Institute Workshop. Interim guidelines
for management of abnormal cervical cytology. JAMA 1994;271:1866--9.
MacKellar DA, Valleroy LA, Secura GM,
et al. Two decades after vaccine license: hepatitis B immunization
and infection among young men who have sex with men. Am J Public Health
2001;91:965--71.
Mast EE, Williams IT, Alter MJ, Margolis
HS. Hepatitis B vaccination of adolescent and adult high-risk groups
in the United States. Vaccine 1998;16(Suppl):S27--S29.
Alter MJ, Kruszon-Moran D, Nainan OV,
et al. The prevalence of hepatitis C virus infection in the United
States, 1988 through 1994. N Engl J Med 1999;341:556--62.
Diegstag JL. Sexual and perinatal transmission
of hepatitis C. Hepatology 1997:26(Suppl 1):S66--S70.
Alter MJ. Epidemiology of hepatitis
C. Hepatology 1999;26(Suppl 1):S25--S65.
Thomas DL, Zenilman JM, Alter MJ, et
al. Sexual transmission of hepatitis C virus among patients attending
Baltimore sexually transmitted disease clinics: an analysis of 309
sex partnerships. J Infect Dis 1995;171:768--75.
Hisada M, O'Brien TR, Rosenberg PS,
Goedert JJ. Virus load and risk of heterosexual transmission of human
immunodeficiency virus and hepatitis C virus by men with hemophilia:
the Multicenter Hemophilia Cohort Study. J Infect Dis 2000;181:1475--8.
Bamberger JD, Waldo CR, Gerberding JL,
Katz MH. Postexposure prophylaxis for human immunodeficiency virus
(HIV) infection following sexual assault. Am J Med 1999;106:323--6.
American Academy of Pediatrics. Sexually
transmitted disease in adolescents and children. In: Pickering LK,
ed. 2000 Red book: report of the Committee on Infectious Diseases.
25th ed. Elk Grove Village, IL: American Academy of Pediatrics,
2000:138--47.
American Academy of Pediatrics Committee
on Child Abuse and Neglect. Guidelines for the evaluation of sexual
abuse of children: subject review. Pediatrics 1999;103:186--91.
Adams JA, Harper K, Krudson S. A proposed
system for the classifications of anogenital findings in children with
suspected child abuse. Adolesc Pediatr Gynecol 1992;5:73--5.
Shapiro RA, Schubert CJ, Siegel R. Neisseria
gonorrhoeae infections in girls younger than 12 years of age
evaluated for vaginitis. Pediatrics 1999;104:(e72):1--11.
Lagerberg D. Sexually transmitted diseases
in children: a serious consequence of sexual abuse and an indication
of possible victimization of other children. Acta Pediatrica 1998;87:1214--7.
Dominguez KL, Simonds RJ. Postexposure
prophylaxis. In: Zeichner SL, Read JS, eds. Handbook of pediatric HIV
care. Philadelphia: Lippincott Williams & Wilkins, 1999:294--318.
Abbreviations Used in This Publication
ACIP
Advisory Committee on Immunization Practices
ACOG
American College of Obstetricians and Gynecologists
ACS
American Cancer Society
AIDS
Acquired immunodeficiency syndrome
ALT
Alanine aminotransferase
anti-HBc
Antibody to the hepatitis B core antigen
ASCUS
Atypical squamous cells of undetermined significance
BCA
Bichloroacetic acid
BV
Bacterial vaginosis
CBC
Complete blood count
CDC
Centers for Disease Control and Prevention
CI
Confidence interval
CIN
Cervical intraepithelial neoplasia
CLD
Chronic liver disease
CMV
Cytomegalovirus
CNS
Central nervous system
CSF
Cerebrospinal fluid
d4T
Stavudine
ddC
Dideoxycytodine
ddI
Didanosine
DFA
Direct fluorescent antibody
DGI
Disseminated gonococcal infection
dL
Deciliter
DNA
Deoxyribonucleic acid
EIA
Enzyme immunoassay
ELISA
Enzyme-linked immunosorbent assay
FDA
Food and Drug Administration
FTA-ABS
Fluorescent treponemal antibody absorbed
gG
glycoprotein G
GISP
Gonococcal Isolate Surveillance Project
HAV
Hepatitis A virus
HBIG
Hepatitis B immune globulin
HBsAg
Hepatitis B surface antigen
HBV
Hepatitis B virus
HCV
Hepatitis C virus
HIV
Human immunodeficiency virus
HPV
Human papillomavirus
HSV
Herpes simplex virus
HTLV-1
Human T-cell lymphotrophic virus type I
IDV
Indinavir
IDU
Injection drug user
IFA
Immunofluorescence assay
IgE
Immunoglobulin E
Ig
Immune globulin
IgG
Immunoglobulin G
IHPS
Infantile hypertrophic pyloric stenosis
IM
Intramuscularly
IV
Intravenous or intravenously
kg
Kilogram
KOH
Potassium hydroxide
LGV
Lymphogranuloma venereum
MAC
Mycobacterium avium complex
mg
Milligram
MIC
Minimum inhibitory concentration
MMWR
Morbidity and Mortality Weekly Report
MPC
Mucopurulent cervicitis
MRL
Microbiology Reference Library
MSM
Men who have sex with men
N-9
Nonoxynol-9
NAAT
Nucleic acid amplification test
NGU
Nongonococcal urethritis
OTC
Over-the-counter
Pap
Papanicolaou
PCP
Pneumocystis carinii pneumonia
PCR
Polymerase chain reaction
PEP
Postexposure prophylaxis
PID
Pelvic inflammatory disease
PPD
Purified protein derivative
PPV
Positive predictive value
QRNG
Quinolone resistant Neisseria gonorrhoeae
RIBA
Recombinant immunoblot assay
RNA
Ribonucleic acid
RPR
Rapid plasma reagin
RT-PCR
Reverse transcriptase polymerase chain reaction
RVVC
Recurrent vulvovaginal candidiasis
SAQ
Saquinavir
SIL
Squamous intraepithelial lesion
STD
Sexually transmitted disease
TB
Tuberculosis
TCA
Trichloroacetic acid
TE
Toxoplasmic encephalitis
TMP-SMX
Trimethoprim-sulfamethoxazole
TP-PA
Treponema pallidum particle agglutation
TST
Tuberculin skin test
VDRL
Venereal Disease Research Laboratory
VFC
Vaccines for children
VVC
Vulvovaginal candidiasis
WB
Western blot
WBC
White blood count
ZDV
Zidovudine
3TC
Lamivudine
Consultants
Chairpersons: David Atkins, M.D., M.P.H., Agency for Healthcare
Research and Quality, Rockville, MD; Kimberly A. Workowski, M.D., Division
of STD Prevention, CDC and Emory University, Atlanta, GA.
Presenters: Adaora A. Adimora, M.D., M.P.H., University of North
Carolina, Chapel Hill, NC; Michael H. Augenbraun, M.D., State University
of New York (SUNY) Health Science Center, Brooklyn, NY; Willard Cates,
Jr., M.D., M.P.H., Family Health International, Research Triangle Park,
NC; Jane Cecil, M.D., Johns Hopkins, Baltimore, MD; Lynne Fukumoto, UCLA
School of Nursing, Los Angeles, CA; Margaret Hammerschlag, M.D., SUNY
Health Science Center, Brooklyn, NY; Anne M. Rompalo, M.D., Johns Hopkins
University, Baltimore, MD; Richard Rothenberg, M.D., Emory University
School of Medicine, Atlanta, GA; Pablo J. Sanchez, M.D., University of
Texas Southwestern Medical Center, Dallas, TX; Bradley Stoner, M.D.,
Ph.D., Washington University School of Medicine, St. Louis, MO; Jane
R. Schwebke, M.D., Department of Medicine, University of Alabama, Birmingham,
AL; Anna Wald, M.D., M.P.H., University of Washington, Seattle, WA; Cheryl
K. Walker, M.D., Stanford University Medical Center, Stanford, CA; George
D. Wendel, M.D., University of Texas Southwestern Medical Center, Dallas,
TX; Karen Wendel, M.D., Johns Hopkins University, Baltimore, MD; Dorothy
J. Wiley, Ph.D., UCLA School of Nursing, Los Angeles, CA; Jonathan M.
Zenilman, M.D., Johns Hopkins University, Baltimore, MD. Moderators: King
K. Holmes, M.D., Ph.D., Center for AIDS and STDs, University of Washington,
Seattle, WA; Edward W. Hook, III, M.D., University of Alabama, School
of Medicine, Birmingham, AL; William McCormack, M.D., SUNY Health Science
Center, Brooklyn, NY. Rapporteurs: John M. Douglas, Jr., M.D.,
Denver Department of Public Health and University of Colorado Health
Science Center, Denver, CO; H. Hunter Handsfield, M.D., University of
Washington and Public Health-Seattle & King County, Seattle, WA;
Walter Stamm, M.D., University of Washington Medical Center, Seattle,
WA.
Consultants: Gail Bolan, M.D., California Dept. of Health, Berkeley,
CA; Toye H. Brewer, M.D., University of Miami, Miami, FL; Virginia A.
Caine, M.D., Indiana University School of Medicine, Indianapolis, MN;
Connie Celum, M.D., M.P.H., University of Washington, Seattle, WA; Myron
S. Cohen, M.D., University of North Carolina, Chapel Hill, NC; Thomas
A. Farley, M.D., M.P.H., Tulane University School of Public Health and
Tropical Medicine, New Orleans, LA; Laura T. Gutman, M.D., Duke University,
Durham, NC; Penelope J. Hitchcock, D.V.M., M.S., National Institute for
Allergy and Infectious Diseases, NIH, Bethesda, MD; Sharon Hillier, Ph.D,
Magee Women's Hospital, Pittsburgh, PA; Franklyn N. Judson, M.D., Denver
Department of Health, Denver, CO; David Martin, M.D., LSU Medical Center,
New Orleans, LA; Daniel M. Musher, M.D., Veterans Affairs Medical Center,
Houston, TX; Newton G. Osborne, M.D., M.P.H., Howard University Hospital,
Washington, DC; Jeff Peipert, M.D., M.P.H., Women and Infants Hospital,
Providence, RI; Peter Rice, M.D., Boston Medical Center, Boston, MA;
Mary Sawyer, M.D., Emory University, Atlanta, GA; Jack Sobel, M.D., Wayne
State University, Detroit, MI; David Soper, M.D., Medical University
of South Carolina, Charleston, SC; Lawrence R. Stanberry, M.D., Ph.D.,
University of Texas Medical Branch, Galveston, TX; Barbara Stoll, M.D.,
Emory University School of Medicine, Atlanta, GA; Richard Sweet, M.D.,
Magee Women's Hospital, Pittsburgh, PA; Eugene Washington, M.D., UCSF/Mt.
Zion Medical Center, San Francisco, CA; Heather Watts, M.D., National
Institutes of Health, Bethesda, MD.
Liaison Participants: Vagan A. Akovbian, M.D., Ph.D., Russian
Ministry of Health Central Institute, Moscow, Russia; Gale Burstein,
M.D., M.P.H, American Academy of Pediatrics; Willa Brown, M.D., M.P.H.,
American College of Preventative Medicine; Mike Catchpole, M.D., PHLS
Communicable Disease Surveillance, England; Tom Cox, M.D., American Social
Health Association; William Dumas, R.N., National Coalition of STD Directors;
Antonio C. Gerbase, M.D., World Health Organization; Sharon Hillier,
Ph.D., Infectious Disease Society of Obstetrics and Gynecology; Louella
Klein, M.D., American College of Obstetrics and Gynecology; David J.
Magid, M.D., M.P.H, Managed Care Colorado; Rafael Mazin, M.D., Pan American
Health Organization; Gregory J. Moran, M.D., American College of Emergency
Physicians; Donna Richmond, M.P.H., R.N., Association of Reproductive
Health Professionals; Anthony Schaeffer, M.D., American Urological Association;
Felicia Stewart, M.D., American Social Health Association; Stephen K.
Tyring, M.D., Ph.D., American Academy of Dermatology; Leonard B. Weiner,
M.D., American Academy of Pediatrics; Tom Wong, M.D., M.P.H., Health
Canada.
CDC/Division of STD Prevention (DSTDP)/STD Treatment Guidelines 2002
Project Coordinators: Kimberly A. Workowski, M.D., DSTDP; William
C. Levine, M.D., M.Sc., DSTDP.